Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study

Magdalena E. Sobieszczyk, Donald R. Hoover, Kathryn Anastos, Kathleen Mulligan, Tianren Tan, Qiuhu Shi, Wei Gao, Charles Hyman, Mardge H. Cohen, Stephen R. Cole, Michael W. Plankey, Alexandra M. Levine, Jessica Justman

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

OBJECTIVES: To assess the prevalence of metabolic syndrome (MetSynd) among participants of the Women's Interagency HIV Study and to describe the association of MetSynd with HIV infection, antiretroviral therapies, and sociodemographic factors. METHODS: Prevalence of MetSynd, defined by updated Adult Treatment Panel III guidelines, was assessed among 2393 (1725 seropositive and 668 seronegative) participants from the Women's Interagency HIV Study seen between October 2000 and October 2004. RESULTS: HIV-1 infection was independently associated with MetSynd [33% vs 22%, P < 0.0001 in HIV-seropositive compared with HIV-seronegative women; adjusted odds ratio (OR) 1.79 (95% confidence interval 1.48, 2.16)]. HIV-infected women had higher mean triglyceride (154 vs 101 mg/dL, P < 0.0001) and lower mean high-density lipoprotein cholesterol levels (46 vs 55 mg/dL, P < 0.0001). Most notable factors associated with higher prevalence of MetSynd among HIV-infected women included older age (OR = 1.38 per 5 year increase, P < 0.0001); higher body mass index; current smoking; HIV-1 RNA (OR = 1.36, P = 0.019, for >50,000 vs <80 copies/mL); and use of stavudine (OR = 1.28, P = 0.009). Nevirapine use was protective (OR = 0.75, P = 0.016). There was no significant association of MetSynd with ritonavir-boosted protease inhibitors (OR = 1.15, P = 0.134). CONCLUSIONS: MetSynd is more prevalent in HIV-seropositive than HIV-seronegative women. This increased prevalence was due to dyslipidemias rather than higher blood pressure, glucose, or waist circumference.

Original languageEnglish (US)
Pages (from-to)272-280
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume48
Issue number3
DOIs
StatePublished - Jul 1 2008

Fingerprint

HIV
HIV Infections
Stavudine
Nevirapine
Ritonavir
Waist Circumference
Dyslipidemias
Protease Inhibitors
Blood Glucose
HIV-1
Guidelines
Hypertension
Therapeutics

Keywords

  • HIV
  • Metabolic syndrome
  • Prevalence
  • Women

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Virology
  • Immunology

Cite this

Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study. / Sobieszczyk, Magdalena E.; Hoover, Donald R.; Anastos, Kathryn; Mulligan, Kathleen; Tan, Tianren; Shi, Qiuhu; Gao, Wei; Hyman, Charles; Cohen, Mardge H.; Cole, Stephen R.; Plankey, Michael W.; Levine, Alexandra M.; Justman, Jessica.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 48, No. 3, 01.07.2008, p. 272-280.

Research output: Contribution to journalArticle

Sobieszczyk, ME, Hoover, DR, Anastos, K, Mulligan, K, Tan, T, Shi, Q, Gao, W, Hyman, C, Cohen, MH, Cole, SR, Plankey, MW, Levine, AM & Justman, J 2008, 'Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study', Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 3, pp. 272-280. https://doi.org/10.1097/QAI.0b013e31817af461
Sobieszczyk, Magdalena E. ; Hoover, Donald R. ; Anastos, Kathryn ; Mulligan, Kathleen ; Tan, Tianren ; Shi, Qiuhu ; Gao, Wei ; Hyman, Charles ; Cohen, Mardge H. ; Cole, Stephen R. ; Plankey, Michael W. ; Levine, Alexandra M. ; Justman, Jessica. / Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study. In: Journal of Acquired Immune Deficiency Syndromes. 2008 ; Vol. 48, No. 3. pp. 272-280.
@article{0b3a17d9c23e4e38aa1c417448aeec87,
title = "Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study",
abstract = "OBJECTIVES: To assess the prevalence of metabolic syndrome (MetSynd) among participants of the Women's Interagency HIV Study and to describe the association of MetSynd with HIV infection, antiretroviral therapies, and sociodemographic factors. METHODS: Prevalence of MetSynd, defined by updated Adult Treatment Panel III guidelines, was assessed among 2393 (1725 seropositive and 668 seronegative) participants from the Women's Interagency HIV Study seen between October 2000 and October 2004. RESULTS: HIV-1 infection was independently associated with MetSynd [33{\%} vs 22{\%}, P < 0.0001 in HIV-seropositive compared with HIV-seronegative women; adjusted odds ratio (OR) 1.79 (95{\%} confidence interval 1.48, 2.16)]. HIV-infected women had higher mean triglyceride (154 vs 101 mg/dL, P < 0.0001) and lower mean high-density lipoprotein cholesterol levels (46 vs 55 mg/dL, P < 0.0001). Most notable factors associated with higher prevalence of MetSynd among HIV-infected women included older age (OR = 1.38 per 5 year increase, P < 0.0001); higher body mass index; current smoking; HIV-1 RNA (OR = 1.36, P = 0.019, for >50,000 vs <80 copies/mL); and use of stavudine (OR = 1.28, P = 0.009). Nevirapine use was protective (OR = 0.75, P = 0.016). There was no significant association of MetSynd with ritonavir-boosted protease inhibitors (OR = 1.15, P = 0.134). CONCLUSIONS: MetSynd is more prevalent in HIV-seropositive than HIV-seronegative women. This increased prevalence was due to dyslipidemias rather than higher blood pressure, glucose, or waist circumference.",
keywords = "HIV, Metabolic syndrome, Prevalence, Women",
author = "Sobieszczyk, {Magdalena E.} and Hoover, {Donald R.} and Kathryn Anastos and Kathleen Mulligan and Tianren Tan and Qiuhu Shi and Wei Gao and Charles Hyman and Cohen, {Mardge H.} and Cole, {Stephen R.} and Plankey, {Michael W.} and Levine, {Alexandra M.} and Jessica Justman",
year = "2008",
month = "7",
day = "1",
doi = "10.1097/QAI.0b013e31817af461",
language = "English (US)",
volume = "48",
pages = "272--280",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study

AU - Sobieszczyk, Magdalena E.

AU - Hoover, Donald R.

AU - Anastos, Kathryn

AU - Mulligan, Kathleen

AU - Tan, Tianren

AU - Shi, Qiuhu

AU - Gao, Wei

AU - Hyman, Charles

AU - Cohen, Mardge H.

AU - Cole, Stephen R.

AU - Plankey, Michael W.

AU - Levine, Alexandra M.

AU - Justman, Jessica

PY - 2008/7/1

Y1 - 2008/7/1

N2 - OBJECTIVES: To assess the prevalence of metabolic syndrome (MetSynd) among participants of the Women's Interagency HIV Study and to describe the association of MetSynd with HIV infection, antiretroviral therapies, and sociodemographic factors. METHODS: Prevalence of MetSynd, defined by updated Adult Treatment Panel III guidelines, was assessed among 2393 (1725 seropositive and 668 seronegative) participants from the Women's Interagency HIV Study seen between October 2000 and October 2004. RESULTS: HIV-1 infection was independently associated with MetSynd [33% vs 22%, P < 0.0001 in HIV-seropositive compared with HIV-seronegative women; adjusted odds ratio (OR) 1.79 (95% confidence interval 1.48, 2.16)]. HIV-infected women had higher mean triglyceride (154 vs 101 mg/dL, P < 0.0001) and lower mean high-density lipoprotein cholesterol levels (46 vs 55 mg/dL, P < 0.0001). Most notable factors associated with higher prevalence of MetSynd among HIV-infected women included older age (OR = 1.38 per 5 year increase, P < 0.0001); higher body mass index; current smoking; HIV-1 RNA (OR = 1.36, P = 0.019, for >50,000 vs <80 copies/mL); and use of stavudine (OR = 1.28, P = 0.009). Nevirapine use was protective (OR = 0.75, P = 0.016). There was no significant association of MetSynd with ritonavir-boosted protease inhibitors (OR = 1.15, P = 0.134). CONCLUSIONS: MetSynd is more prevalent in HIV-seropositive than HIV-seronegative women. This increased prevalence was due to dyslipidemias rather than higher blood pressure, glucose, or waist circumference.

AB - OBJECTIVES: To assess the prevalence of metabolic syndrome (MetSynd) among participants of the Women's Interagency HIV Study and to describe the association of MetSynd with HIV infection, antiretroviral therapies, and sociodemographic factors. METHODS: Prevalence of MetSynd, defined by updated Adult Treatment Panel III guidelines, was assessed among 2393 (1725 seropositive and 668 seronegative) participants from the Women's Interagency HIV Study seen between October 2000 and October 2004. RESULTS: HIV-1 infection was independently associated with MetSynd [33% vs 22%, P < 0.0001 in HIV-seropositive compared with HIV-seronegative women; adjusted odds ratio (OR) 1.79 (95% confidence interval 1.48, 2.16)]. HIV-infected women had higher mean triglyceride (154 vs 101 mg/dL, P < 0.0001) and lower mean high-density lipoprotein cholesterol levels (46 vs 55 mg/dL, P < 0.0001). Most notable factors associated with higher prevalence of MetSynd among HIV-infected women included older age (OR = 1.38 per 5 year increase, P < 0.0001); higher body mass index; current smoking; HIV-1 RNA (OR = 1.36, P = 0.019, for >50,000 vs <80 copies/mL); and use of stavudine (OR = 1.28, P = 0.009). Nevirapine use was protective (OR = 0.75, P = 0.016). There was no significant association of MetSynd with ritonavir-boosted protease inhibitors (OR = 1.15, P = 0.134). CONCLUSIONS: MetSynd is more prevalent in HIV-seropositive than HIV-seronegative women. This increased prevalence was due to dyslipidemias rather than higher blood pressure, glucose, or waist circumference.

KW - HIV

KW - Metabolic syndrome

KW - Prevalence

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=47049111149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049111149&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31817af461

DO - 10.1097/QAI.0b013e31817af461

M3 - Article

C2 - 18545157

AN - SCOPUS:47049111149

VL - 48

SP - 272

EP - 280

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -